Working… Menu

Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01880840
Recruitment Status : Completed
First Posted : June 19, 2013
Results First Posted : June 29, 2015
Last Update Posted : June 29, 2015
Novella Clinical
Information provided by (Responsible Party):
Meda Pharmaceuticals

Brief Summary:
The purpose of this study is to compare the safety of 2 different doses of the investigational use of an allergy medication (Astepro Nasal Spray) in the treatment of allergic rhinitis (AR). This is an open-label study; that is, parent and child will know which group each is in.

Condition or disease Intervention/treatment Phase
Allergic Rhinitis Drug: 205.5 mcg of azelastine hydrochloride Drug: 137 mcg of azelastine hydrochloride Phase 4

Detailed Description:

Approximately 200 subjects, between the ages of ≥ 6 months to < 6 years of age who have a history of AR will participate in this study.

The study will be conducted at about 20 research centers in the United States. Each research center will enroll approximately 2 to 10 subjects.

The study will involve at least 4 office visits over at least a 4-week period. You will need to keep the appointments as scheduled by the study personnel.

Some medications or therapies could interfere with the safety evaluations conducted in this study. If your child is currently taking any of these medications or therapies, they will need to discontinue them in order to be eligible for this study. Your study doctor will discuss this with you along with information on how this could affect your child's health. If you and the study doctor decide this is appropriate, there is a specific time period that these will need to be discontinued before your child can proceed in study evaluation.

If your child is eligible for study participation, he/she will be randomly assigned (by chance, like the flip of a coin) to one of the following two study drug groups:

  • Astepro (azelastine hydrochloride) 0.15% Nasal Spray, 822 mcg (total daily dose); OR
  • Astepro (azelastine hydrochloride) 0.1% Nasal Spray, 548 mcg (total daily dose)

The following are being performed for the purposes of this study and are not considered standard care:

  • Your child will be placed in one of the two study drug groups by chance.
  • You will complete questionnaires about your child's allergy symptoms.
  • You will complete diary cards each morning recording your child's allergy symptoms over the previous 24 hours.
  • Your child will have his/her vital signs measured (blood pressure, pulse, temperature and breathing rate).
  • You and your child will be asked questions regarding your child's use of any medication or supplements and how your child has felt since his/her last visit.
  • Blood and urine samples will be collected to assess the safety of taking the study drug.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 191 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Trial of the Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With Allergic Rhinitis
Study Start Date : June 2013
Actual Primary Completion Date : April 2014
Actual Study Completion Date : August 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Astepro 0.15% Nasal Spray
Nasal Spray at a dosage of 1 spray per nostril twice daily
Drug: 205.5 mcg of azelastine hydrochloride
nasal spray
Other Name: astepro .15%

Active Comparator: Astepro 0.1% Nasal Spray
Nasal Spray at a dosage of 1 spray per nostril twice daily
Drug: 137 mcg of azelastine hydrochloride
nasal spray
Other Name: astepro .1%

Primary Outcome Measures :
  1. Safety [ Time Frame: one month of treatment ]

    The objective of this clinical trial is to evaluate the safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray at a dosage of 1 spray per nostril twice daily in subjects ≥6months to <6 years of age with allergic rhinitis.

    Safety will be assessed on the basis of reported adverse experiences, nasal examinations, laboratory evaluations, and vital signs assessments.

    Data for each age strata will be summarized separately as well as combined.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Months to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female subjects >6 months to <6 years, inclusive at the screening visit
  • A history of AR
  • The parent must provide written informed consent and the child must provide assent, if possible
  • Willing and able to comply with the study requirements
  • May benefit from treatment with Astepro Nasal Spray, based on the Investigator's assessment (based on medical history, physical examination, etc.) of the subject's clinical condition, at both the Screening and Randomization Visits
  • General good health and free of any disease or concomitant treatment that could interfere with the interpretation of the study results as determined by the investigator or the sponsor's medical officer
  • Subjects receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit (adjustments to regimen following a brief period of missed injections do not preclude participation)

Exclusion Criteria:

  • On nasal examination, subjects with superficial nasal mucosal erosion, moderate nasal mucosal erosion, nasal mucosal ulceration, nasal septum perforation
  • Other nasal disease(s) likely to affect deposition of intranasal medication, such as acute sinusitis, rhinitis medicamentosa or clinically significant polyposis or nasal structural abnormalities
  • Nasal surgery or sinus surgery within the previous year
  • Chronic sinusitis
  • The use of any investigational drug within 30 days prior to Visit 1. No investigational products are permitted for use during the conduct of this study
  • Presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol or sucralose (Splenda® brand sweetener)
  • Respiratory tract infections within two weeks prior to Visit 1.
  • Subjects with significant pulmonary disease including asthma. Subjects with intermittent asthma who only require short-acting inhaled bronchodilators are eligible for enrollment. Asthma (with the exception of intermittent asthma). Subjects with intermittent asthma who only require short-acting inhaled bronchodilators (not more often than twice per week) and who do not have nocturnal awakening as a result of asthma are eligible for enrollment
  • Chronic obstructive sleep apnea syndrome (clinical diagnosis)
  • Existence of any surgical or medical condition, which in the opinion of the investigator or sponsor's medical monitor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug or that might significantly affect the subject's ability to complete this trial
  • Clinically relevant abnormal physical findings or laboratory results which, in the opinion of the investigator, would interfere with the objectives -- Family members of research center or private practice personnel who are directly involved in this study are excluded
  • Members of the same family cannot enroll in the study at the same time.
  • Subjects who have used medications or therapies that could interfere with safety evaluations (see Section 4.0)
  • Any behavioral condition which could affect subject's ability to accurately report symptoms to the caregiver such as developmental delay, attention deficit disorder, and autism

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01880840

Layout table for location information
United States, Alabama
Clinical Research Center of Alabama,LLC
Birmingham, Alabama, United States, 35209
United States, Alaska
Little Rock Allergy and Asthma Clinical research Center
Little Rock, Alaska, United States, 72205
United States, California
West Coast Clinical Trials
Costa Mesa, California, United States, 92626
Southern California Research
Mission Viejo, California, United States, 92691
United States, Colorado
Storms Clinical Research Institute
Colorado Springs, Colorado, United States, 80907
United States, Illinois
Sneeze, Wheeze and Itch Associates
Normal, Illinois, United States, 61761
United States, Oklahoma
Allergy, Asthma & Clinical Research Center
Oklahoma City, Oklahoma, United States, 73120
United States, Pennsylvania
National Allergy, Asthna & Urticaria Centers of Charleston Pa
Charleston, Pennsylvania, United States, 29406
United States, Texas
Texas Allergy Research Center
Dallas, Texas, United States, 75246
Central Texas Health Research
New Braunfels, Texas, United States, 78130
Paul H Ratner,MD
San Antonio, Texas, United States, 78229
Live Oak Allergy and Asthma Clinic
San Antonio, Texas, United States, 78233
Allergy and Asthma Center
Waco, Texas, United States, 76712
Pediatric Allergy,Asthma and Immunology/Allergy& Asthma care of Waco
Waco, Texas, United States, 76712
Sponsors and Collaborators
Meda Pharmaceuticals
Novella Clinical
Layout table for additonal information
Responsible Party: Meda Pharmaceuticals Identifier: NCT01880840    
Other Study ID Numbers: MP 442
First Posted: June 19, 2013    Key Record Dates
Results First Posted: June 29, 2015
Last Update Posted: June 29, 2015
Last Verified: April 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis, Allergic
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Lipoxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Allergic Agents
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents